Preliminary safety data from a French registry on combination therapy in immune-mediated inflammatory diseases (IMIDs) show a concerning rate of serious infections and illustrate the need for ...

Patients with psoriasis who experienced secukinumab secondary failure did not require switching after experiencing significant improvement of daily functioning and quality of life when given a ...

CHICAGO — Levothyroxine (LT4) monotherapy remains the standard treatment for hypothyroidism, although a subset of patients continue to have hypothyroidism despite normal thyroid-stimulating hormone ...

Treatments for rheumatoid arthritis (RA) curb inflammation in your body, protect your joints from damage, and ease symptoms like pain and stiffness. But sometimes one drug isn't enough to keep RA ...

At the American Society of Clinical Oncology (ASCO) annual meeting, promising results were reported from two trials that evaluated a combination of two bispecific antibodies in patients with relapsed ...

Please provide your email address to receive an email when new articles are posted on . Entyvio and Stelara were commonly used in combination therapy for the treatment of inflammatory bowel disease, ...

Samuraciclib, a CDK7 inhibitor, shows promise in HR-positive advanced breast cancer post-CDK4/6 inhibitor therapy, with extended PFS in specific patient groups. MORPHEUS and Module 2A trials highlight ...

A strategy that combines high-intensity statin therapy with ezetimibe early after myocardial infarction results in a lower risk of recurrent events when contrasted with approaches that start ...

AbbVie recently received full FDA approval for EPKINLY (epcoritamab-bysp) in combination with rituximab and lenalidomide for the treatment of adults with relapsed or refractory follicular lymphoma, ...